Tech highlights lung tumours for better removal


Thursday, 02 April, 2020



Tech highlights lung tumours for better removal

A groundbreaking technology that enhances lung cancer tissue is providing surgeons with a significantly better chance of finding and removing more cancer than ever before.

Near-infrared imaging with OTL38 during surgery for lung cancer is a promising technology, with the potential to significantly improve the completeness and quality of tumour removal.

Dr Inderpal (Netu) S Sarkaria from the University of Pittsburgh Medical Center in Pennsylvania — along with colleagues from six institutions — conducted a phase II trial in 92 patients with lung lesions who were to undergo pulmonary resection for non-small cell lung cancer (NSCLC).

Before their operations, each patient received a measured intravenous dose of OTL38, composed of near-infrared dye and a targeting molecule. The molecule attaches to folic acid-based receptors on cancer cells and can be illuminated during surgery using a special surgical endoscope. This helps identify small, hard-to-detect cancer lesions that should be surgically removed but might otherwise have been missed.

The researchers made assessments in three phases: lung inspection, tumour resection and specimen check.

During the inspection phase, molecular imaging identified 10 additional cancers (that were missed when using visual examination and manual touch) in seven patients (8%).

In the resection phase, researchers determined that OTL38 enabled localisation of lesions that were not found in 11 patients (12%).

After the surgeons found that all margins were visually adequate or clear in the specimen check, the resected specimens were further assessed using molecular imaging. Inadequate margins (microscopic residual tumour left at the edges) were uncovered in eight patients (9%).

Overall, the researchers determined that OTL38 molecular imaging helped improve outcomes for one in four patients (26%).

“OTL38 is the first technique that is specific to imaging adenocarcinomas of the lung, which is one of the most common types of invasive lung cancer, making it unique and clinically useful in this respect,” Dr Sarkaria said.

“Localisation of tumours, identification of occult tumours and immediate tumour margin assessment during surgery for adenocarcinomas of the lung were significantly improved with the use of this technology.”

Surgery remains the best potentially curative treatment for early-stage NSCLC. However, research has shown that 30 to 55% of patients with NSCLC develop recurrence, which often is caused by microscopic clusters of cancer cells that were undetected by standard staging methods. This suggests that complete removal needs to be ensured both macroscopically and microscopically during surgery.

“Near-infrared imaging with OTL38 may be a powerful tool to help surgeons significantly improve the quality of lung cancer surgery by more clearly identifying tumours and allowing the surgeon to better see and completely remove them — one of the most vital components in the overall care of patients with this disease,” Dr Sarkaria said.

Surgeons traditionally use X-rays, magnetic resonance imaging, computed tomography (CT) scans, positron emission tomograph and/or ultrasound to determine the size and location of tumours before surgery. However, these imaging modalities are rarely, if ever, used during surgery.

OTL38 is believed to be the first targeted fluorescent marker to provide this type of benefit for lung cancer. The OTL38 technology is different in its ability to detect cancerous tissue not previously identified on preoperative scans and do so in real time, while the surgeon is operating. This is crucial in ensuring that surgeons adequately detect and remove cancer cells that may not be visible to the naked eye or located through touch. The complete removal of diseased tissue during surgery helps to avoid additional surgeries and cancer relapse, as well as increase patients’ overall chances of survival.

“Use of advanced near-infrared imaging techniques such as OTL38 may provide surgeons with powerful tools to improve the quality of lung cancer operations by better identifying small, hard-to-find tumours, finding previously undetected cancers at the time of surgery and better assessing if the entire tumour has been removed,” he explained.

With the implementation of lung screening and the increased use of CT scans in general, cardiothoracic surgeons are seeing more patients with small or undefined nodules, so the availability of technology such as OTL38 is welcome.

“In many circumstances, a preoperative biopsy is not practical or feasible and we are faced with the need for intraoperative identification of these nodules,” University of Virginia’s Dr Linda Martin said.

“This research describes an exciting new approach to localise nodules that are difficult to find without a separate procedure. More importantly, the study showed that because of this technology, additional nodules that were in fact separate cancers were found, and useful information about margin status also resulted.”

Image credit: ©stock.adobe.com/au/BillionPhotos.com

Related Articles

Cancer patients set to benefit from expanded oncology network

Patients will have increased access to the latest oncology treatment technology and research,...

What we know about immunity to coronaviruses

A review of more than 40 studies on coronavirus immunity suggests that SARS-CoV-2 could become...

What factors increase risk of severe COVID-19 or death?

A UK study has revealed that age, male sex, obesity and underlying illness emerge as risk factors...


  • All content Copyright © 2020 Westwick-Farrow Pty Ltd